Treatment of diabetic retinopathy with fully-human post-translationally modified anti-vegf fab
US-2022280608-A1 · Sep 8, 2022 · US
This page is not indexed by search engines while we improve data quality.
Regenxbio Inc patents in 2022
Regenxbio Inc was listed as an assignee on 9 patent publications in 2022.
| Metric | Value |
|---|---|
| Company | Regenxbio Inc |
| Year | 2022 |
| Patents | 9 |
Patents
Representative publications for Regenxbio Inc in 2022.
Methods of size exclusion chromatography for the characterization of recombinant adeno-associated virus compositions
US-2022275358-A1 · Sep 1, 2022 · US
Methods for the treatment of epilepsy
US-2022251567-A1 · Aug 11, 2022 · US
Intranasal administration of adeno-associated virus to treat central nervous system disorders
US-2022211875-A1 · Jul 7, 2022 · US
Fully-human post-translationally modified antibody therapeutics
US-2022195462-A1 · Jun 23, 2022 · US
Top CPC classifications
Most common classification codes for Regenxbio Inc in 2022.
| CPC | Patents |
|---|---|
| C12N2750/14143 | 9 |
| C12N15/86 | 7 |
| C12N7/00 | 5 |
| A61P25/28 | 4 |
| A61P27/02 | 4 |
Related pages
Navigate to parent entity pages.